Literature DB >> 7862451

The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.

R Ferracini1, M F Di Renzo, K Scotlandi, N Baldini, M Olivero, P Lollini, O Cremona, M Campanacci, P M Comoglio.   

Abstract

The c-MET oncogene encodes the receptor for the Hepatocyte Growth Factor/Scatter Factor (HGF), a cytokine that stimulates the invasive growth of normal and neoplastic cells. The Met/HGF receptor is expressed by epithelial cells and its ligand by cells of mesenchymal origin. Receptor-ligand interaction occurs via a paracrine circuit. We studied the expression of the Met/HGF receptor and of its ligand in mesenchymal human tumours by examining 39 clinical samples of bone tumours. The Met/HGF receptor was not detectable in the majority of bone tumours, as expected from their mesenchymal origin. Notably, the receptor was overexpressed in 60% of the osteosarcomas examined. In 12 osteosarcoma cell lines the Met/HGF receptor was overexpressed, phosphorylated by HGF stimulation and fully functional. HGF was detected in two out of seven clinical specimens of osteosarcoma. The ligand and the receptor are co-expressed in two clonal osteosarcoma cell lines. In these lines the Met/HGF receptor was constitutively phosphorylated; phosphorylation was suppressed by suramin treatment, a known blocker of autocrine loops. These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862451

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  78 in total

Review 1.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Authors:  Alla Danilkovitch-Miagkova; Berton Zbar
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

Review 3.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

4.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Alternative proteolytic processing of hepatocyte growth factor during wound repair.

Authors:  Nils Buchstein; Daniel Hoffmann; Hans Smola; Sabina Lang; Mats Paulsson; Catherin Niemann; Thomas Krieg; Sabine A Eming
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 6.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

7.  Preferential expression of RB1-inducible coiled-coil 1 in terminal differentiated musculoskeletal cells.

Authors:  Tokuhiro Chano; Yukikazu Saeki; Massimo Serra; Keiji Matsumoto; Hidetoshi Okabe
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Authors:  Yi Guo; Jun Xie; Elyssa Rubin; Ya-Xiong Tang; Fritz Lin; Xiaolin Zi; Bang H Hoang
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 9.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

10.  C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.

Authors:  Shahid S Siddiqui; Sivakumar Loganathan; Soundararajan Krishnaswamy; Leonardo Faoro; Ramasamy Jagadeeswaran; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2008-03-05       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.